title: A comparative study of amoxicillin-clavulanate and amoxicillin. Treatment of otitis media with effusion.
abstract: A double-blind randomized clinical trial was conducted at two sites comparing amoxicillin-clavulanate potassium (Augmentin) and amoxicillin trihydrate for the treatment of otitis media with effusion ("secretory otitis media"). One hundred eight subjects were randomly assigned to receive a ten-day course of either drug regimen. Clinical response was assessed at ten days and four weeks after entry. For those without middle ear effusion at four weeks, recurrence rates were measured at 8, 12, and 16 weeks after entry. At ten days following entry, 29 (51.8%) of 56 subjects in the amoxicillin-clavulanate-treated group were effusion free compared with 16 (32.0%) of 50 subjects in the amoxicillin-treated group (P = .06). At four weeks following entry, 26 (50.0%) of 50 subjects in the amoxicillin-clavulanate-treated group were effusion free compared with 23 (51.1%) of 45 subjects in the group given amoxicillin. By the 16-week visit, eight (36.4%) of 22 subjects in the amoxicillin-clavulanate-treated group who were effusion free at four weeks had recurrence of effusion, compared with 12 (63.2%) of 19 subjects in the amoxicillin-treated group. This study suggests that there was a favorable clinical response immediately following treatment in the amoxicillin-clavulanate--treated subjects as compared with those treated with amoxicillin, but this benefit was not sustained at the four-week end point.
authors.affiliation: Department of Pediatric Otolaryngology, University of Pittsburgh School of Medicine, PA.
authors.forename: K H
authors.initials: KH
authors.lastname: Chan
authors.forename: E M
authors.initials: EM
authors.lastname: Mandel
authors.forename: H E
authors.initials: HE
authors.lastname: Rockette
authors.forename: C D
authors.initials: CD
authors.lastname: Bluestone
authors.forename: L W
authors.initials: LW
authors.lastname: Bass
authors.forename: M M
authors.initials: MM
authors.lastname: Blatter
authors.forename: J M
authors.initials: JM
authors.lastname: Breck
authors.forename: K S
authors.initials: KS
authors.lastname: Reisinger
authors.forename: J H
authors.initials: JH
authors.lastname: Wolfson
authors.forename: F P
authors.initials: FP
authors.lastname: Wucher
mesh_terms: D000293:Adolescent; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D002648:Child; D002675:Child, Preschool; D002969:Clavulanic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D010034:Otitis Media with Effusion / Q000188:drug therapy*; D010349:Patient Compliance; D011897:Random Allocation; D012008:Recurrence
chemical_list: D002969:Clavulanic Acids; D004338:Drug Combinations; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin